Genetic testing for familial hypercholesterolemia among survivors of acute coronary syndrome

Abstract

Background: Familial hypercholesterolemia could be prevalent among patients with acute coronary syndrome. Objective: To investigate both the frequency of causative mutations for familial hypercholesterolemia (FH) and the optimal selection of patients for genetic testing among patients with an acute coronary syndrome (ACS). Methods: One hundred and sixteen patients with an ACS during 2009–2015 were identified through the SWEDEHEART registry. Patients who had either a high total cholesterol level ≥7 mmol L−1 combined with a triglyceride level ≤2.6 mmol L−1, or were treated with lipid-lowering medication and had a total cholesterol level >4.9 mmol L−1 and a triglyceride level ≤2.6 mmol L−1 were included. Genetic testing was performed first with a regionally designed FH mutation panel (118 mutations), followed by testing with a commercially available FH genetic analysis (Progenika Biopharma). Results: A total of 6.9% (8/116) patients had a FH-causative mutation, all in the LDL-receptor. Five patients were detected on the panel, and further testing of the remaining 111 patients detected an additional 3 FH-causative mutations. Baseline characteristics were similar in FH-positive and FH-negative patients with respect to age, gender, prior ACS and diabetes. Patients with a FH-causative mutation had higher Dutch Lipid Clinical Network (DLCN) score (5.5 (5.0–6.5) vs 3.0 (2.0–5.0), P < 0.001) and a higher low-density lipoprotein level (5.7 (4.7–6.5) vs 4.9 (3.5–5.4), P = 0.030). The Dutch Lipid Clinical Network (DLCN) score had a good discrimination with an area under the curve of 0.856 (95% CI 0.763–0.949). Conclusion: Genetic testing for FH should be considered in patients with ACS and high DLCN score.